An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS) as Monotherapy or in Combination With Ribavirin (COPEGUS) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols [Protocolo multicentrico abierto en el que se proporciona interferon pegilado alfa-2a (PEGASYS) en monoterapia o en combinacion con ribavirina (COPEGUS) a pacientes con hepatitis C cronica que han participado en protocolos de Roche anteriores]

Trial Profile

An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS) as Monotherapy or in Combination With Ribavirin (COPEGUS) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols [Protocolo multicentrico abierto en el que se proporciona interferon pegilado alfa-2a (PEGASYS) en monoterapia o en combinacion con ribavirina (COPEGUS) a pacientes con hepatitis C cronica que han participado en protocolos de Roche anteriores]

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Jun 2012 Status changed from recruiting to completed.as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Planned end date changed from 1 Jul 2015 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top